Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Prospective analysis supports triamcinolone acetonide in Hunner's ulcer subtype IC

Oct. 13, 2009

Nymox reports results from phase II clinical trial of NX-1207 for BPH

Oct. 9, 2009

Promising preclinical data support TRK-380 as a novel candidate for OAB treatment

Oct. 9, 2009

Plethora Solutions reports results from studies of PSD-506 for overactive bladder

Oct. 5, 2009

Roche describes alpha1A-adrenoceptor partial agonists for urinary incontinence

Oct. 2, 2009

Kyorin and Eisai sign license agreement for Uritos for overactive bladder

Oct. 1, 2009

Keryx reports results of open-label extension study of Zerenex for hyperphosphatemia

Sep. 29, 2009

Roche claims alpha1A-adrenoceptor partial agonists for the treatment of urinary incontinence

Sep. 25, 2009

Protox Therapeutics presents 12-month phase II PRX-302 results

Sep. 17, 2009

U.K. launch for Regurin XL for overactive bladder

Sep. 8, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...